CELL THERAPY

细胞疗法

• 批准号: 8245887
• 负责人: James William Young
• 金额: $ 28.04万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8245887
• 关键词: Address; Adoptive Immunotherapy; Allogenic; Allografting; Ambulatory Care Facilities; Antigens; Area; B-Lymphocytes; Biological Assay; Biology; Cell Line; Cell Therapy; Cell physiology; Clinical; Clinical Trials; Cytomegalovirus; Dendritic Cells; Disease; Flow Cytometry; Generations; Hematopoietic Stem Cell Transplantation; Human; Immunobiology; Inpatients; Laboratories; Lymphocyte; Lymphocyte Activation; Lymphoid; Malignant Neoplasms; Marrow; Medical; Monitor; Myelogenous; Natural Killer Cells; Opportunistic Infections; Outcome; Patient Care; Patients; Production; Recurrence; Research; Resources; Siblings; Specimen; Structure of thyroid parafollicular cell; T-Lymphocyte; Transplantation; cost; improved; leukemia; older patient; programs; public health relevance; reconstitution; repository; research and development; translational clinical trial

Core C: Cell Therapy. This is a new core that will take advantage of new physical space resources to consolidate efforts relating to cell therapies developed and applied in this program. This core will therefore provide four specific functions: (1) specimen procurement, prioritization, and distribution for research, in coordination with the Clinical Cytotherapy/Transplant Laboratory, inpatient units, and outpatient clinics, and including a centralized storage repository (all Projects 1-6); (2) graft characterization by flow cytometry, clonogenic assays, and lymphocyte functional assays to develop predictors of graft outcome (Project 6); (3) production and release of NK cells and antigen (CMV and WT-1)-specific T cells for adoptive immunptherapy, including the generation of human dendritic cells and EBV-transformed B cell lines for lymphocyte stimulation and expansion ex vivo (Projects 1, 4, and 6); and (4) coordinated QA/QC oversight of these activities (Project 6). The actual cell processing for hematopoietic stem cell transplantation will remain with the Clinical Cytotherapy Laboratory. Additionally, the activities conducted by the Clinical Cytotherapy Laboratory are largely billable as clinical patient care and do not require support from this core. This core will also interact with Core B by providing the upfront graft characterization that will help interpret posttransplant monitoring of myeloid (including dendritic cell) and lymphoid reconstitution pertinent to graft outcome. The integration of these previously separate efforts will provide greater efficiency of effort and costs, will enhance patient care by improved characterization of allograft biology, and will provide NK and Ag-specific T cell therapies to address major early complications of disease recurrence and opportunistic infections. Lay summary and public health relevance: Fewer complications and the availability of alternative donors to matched siblings have made allogeneic hematopoietic stem cell transplantation available to larger numbers of patients. These include older patients and those with coexisting medical problems. Laboratory support provided by this Core will sustain research and development in this area as well as translational applications in the proposed clinical trials. These activities will help improve the overall outcomes of patients undergoing allogeneic transplant each year for an increasing variety of malignancies.

核心C：细胞疗法。这是一个新的核心，它将利用新的物理空间资源来 合并与该计划开发和应用细胞疗法有关的工作。因此，这个核心将 提供四个特定功能：（1）标本采购，优先级和研究分布 与临床细胞疗法/移植实验室，住院单位和门诊诊所的协调 包括集中存储存储库（所有项目1-6）； （2）通过流式细胞仪进行移植表征， 克隆生成测定和淋巴细胞功能测定，以开发移植结果的预测因子（项目6）； （3） NK细胞和抗原（CMV和WT-1）特异性T细胞的生产和释放用于收养 免疫疗法，包括生成人树突状细胞和EBV转化的B细胞系 淋巴细胞刺激和体内扩张（项目1、4和6）； （4）协调的QA/QC监督 这些活动（项目6）。造血干细胞移植的实际细胞处理将保留 与临床细胞疗法实验室有关。此外，临床细胞疗法进行的活动 实验室在很大程度上是可以作为临床患者护理来计算的，并且不需要此核心的支持。这个核心 还将通过提供前期移植表征来与Core B相互作用，该表征将有助于解释移植后。 与移植有关 结果。这些以前独立的努力的整合将提供更大的努力和 成本，通过改善同种异体移植生物学的特征来增强患者护理，并将提供NK和 Ag特异性T细胞疗法解决疾病复发和机会主义的主要早期并发症 感染。 外行摘要和公共卫生相关性：较少的并发症和替代捐助者的可用性 匹配的兄弟姐妹使同种异体造血干细胞移植可用于较大 患者人数。这些包括老年患者和患有医疗问题的患者。实验室 该核心提供的支持将维持该领域的研发以及翻译 在拟议的临床试验中的应用。这些活动将有助于改善患者的整体结果 每年进行同种异体移植，以种类越来越多的恶性肿瘤。